Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

ProPhase Labs Inc

Healthcare US PRPH

0.141USD
0.0046(3.37%)

Last update at 2026-03-10T19:58:00Z

Day Range

0.130.15
LowHigh

52 Week Range

4.059.75
LowHigh

Fundamentals

  • Previous Close 0.14
  • Market Cap97.68M
  • Volume17139
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-24.11500M
  • Revenue TTM28.71M
  • Revenue Per Share TTM1.64
  • Gross Profit TTM 70.65M
  • Diluted EPS TTM-1.36

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 22.91M 5.30M -2.32600M -3.10600M -1.46700M
Minority interest - - - - -
Net income 18.46M 6.27M -2.42000M -3.01300M -1.74000M
Selling general administrative 46.41M 22.49M 6.67M 4.48M 4.91M
Selling and marketing expenses - - 1.29M 1.04M 1.11M
Gross profit 70.65M 32.81M 4.61M 2.62M 4.78M
Reconciled depreciation 5.06M 3.56M 0.46M 0.40M 0.38M
Ebit 23.59M 9.80M -3.98500M -3.23900M -2.01700M
Ebitda 28.81M 14.01M -3.46500M -2.84100M -1.63400M
Depreciation and amortization 5.21M 4.21M 0.52M 0.40M 0.38M
Non operating income net other - - 0.06M 0.13M -
Operating income 23.59M 9.80M -3.98500M -3.23900M -1.63400M
Other operating expenses 99.05M 69.24M 18.50M 13.12M 14.76M
Interest expense 0.76M 1.15M 0.29M 0.00000M 0.00000M
Tax provision 4.45M -0.96800M - 0.00000M 0.10M
Interest income 0.15M 0.64M 0.06M 0.13M 0.17M
Net interest income -0.61100M -0.50600M -0.23300M 0.13M 0.17M
Extraordinary items - - - -0.04000M -0.17000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.45M -0.96800M 0.09M -0.09300M 0.10M
Total revenue 122.65M 79.04M 14.51M 9.88M 13.13M
Total operating expenses 47.06M 23.01M 8.59M 5.85M 6.42M
Cost of revenue 51.99M 46.23M 9.91M 7.26M 8.35M
Total other income expense net -0.68700M -4.49600M 1.66M 0.13M 0.17M
Discontinued operations - - 0.20M -0.04000M -0.17000M
Net income from continuing ops 18.46M 6.27M -2.32600M -3.10600M -1.57000M
Net income applicable to common shares - 6.27M -2.12500M -3.14600M -1.74000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 91.93M 87.65M 89.30M 31.41M 12.27M
Intangible assets 12.33M 8.47M 10.85M 1.23M -
Earning assets - - - - -
Other current assets 2.15M 2.37M 1.50M 1.24M 0.30M
Total liab 42.54M 24.02M 30.67M 20.85M 1.04M
Total stockholder equity 49.38M 63.63M 58.63M 10.56M 11.23M
Deferred long term liab - - - - -
Other current liab 6.30M 7.37M 5.80M 2.02M 0.40M
Common stock 0.02M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.01M
Retained earnings -5.02900M 11.75M 2.64M -3.63100M -1.50600M
Other liab - 1.28M 0.91M 0.16M 0.11M
Good will 5.23M 5.71M 5.71M 0.90M -
Other assets - 1.28M 1.07M 0.00817M -
Cash 2.15M 9.11M 8.41M 6.82M 0.43M
Cash and equivalents - - - - -
Total current liabilities 20.86M 16.07M 15.52M 6.29M 0.93M
Current deferred revenue 2.38M 2.50M 2.03M 0.17M 0.10M
Net debt 19.23M -2.14900M 6.49M 7.91M -0.43400M
Short term debt 2.79M 0.30M 0.66M 0.33M -
Short long term debt - - - - -
Short long term debt total 21.38M 6.96M 14.90M 14.72M 0.93M
Other stockholder equity 54.69M 51.10M 56.15M 14.18M 12.72M
Property plant equipment - - 10.35M 8.31M 2.33M
Total current assets 47.59M 60.83M 61.32M 15.89M 9.95M
Long term investments - - - - -
Net tangible assets - - 42.07M 8.42M 11.23M
Short term investments 3.13M 8.33M 8.86M 1.64M 0.93M
Net receivables 36.31M 37.05M 37.71M 3.15M 6.82M
Long term debt 10.26M 2.40M 10.04M 9.99M -
Inventory 3.84M 3.98M 4.60M 3.04M 1.46M
Accounts payable 9.38M 5.91M 7.03M 3.77M 0.43M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.30000M 0.76M -0.17500M -0.01100M -0.00200M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00001M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -3.63100M -1.50600M
Treasury stock - - - -47.49000M -47.49000M
Accumulated amortization - - - - -
Non currrent assets other -10.33800M 1.28M 1.07M 5.07M 2.33M
Deferred long term asset charges - - - - -
Non current assets total 44.34M 26.82M 27.98M 15.52M 2.33M
Capital lease obligations 11.12M 4.56M 4.86M 4.73M -
Long term debt total - - - 9.99M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.07700M -19.66600M -0.72000M 5.77M 12.00M
Change to liabilities 0.48M 5.06M 3.34M -0.26100M -0.44900M
Total cashflows from investing activities - -19.66600M -1.01600M 5.54M 11.86M
Net borrowings - -0.04500M 10.00M 10.00M 10.00M
Total cash from financing activities -26.02300M 35.13M 9.99M -5.82200M -11.36200M
Change to operating activities - 0.27M -1.44000M -0.25500M -0.19800M
Net income 18.46M 6.27M -2.12500M -3.14600M -1.74000M
Change in cash 0.45M 1.84M 6.38M -1.12000M -1.61900M
Begin period cash flow 8.66M 6.82M 0.43M 1.55M 3.17M
End period cash flow 9.11M 8.66M 6.82M 0.43M 1.55M
Total cash from operating activities 28.55M -13.61900M -2.59200M -0.84100M -2.11900M
Issuance of capital stock 0.00000M 40.63M - - -
Depreciation 5.06M 3.56M 0.46M 0.40M 0.38M
Other cashflows from investing activities - -0.70000M 1.81M 5.77M 0.00100M
Dividends paid 9.35M 4.55M 0.00000M 5.82M 11.70M
Change to inventory 0.70M -1.74600M -1.46800M 0.44M -0.37200M
Change to account receivables -4.49800M -30.46600M -1.03900M 0.94M -1.02300M
Sale purchase of stock -9.62600M -0.91700M - - 0.34M
Other cashflows from financing activities -14.51800M -19.66600M 9.99M 5.54M 0.34M
Change to netincome 9.36M 11.15M -0.31800M 0.80M 0.93M
Capital expenditures 3.92M 4.23M 1.69M 0.23M 0.14M
Change receivables - - -1.03900M 0.94M -1.02300M
Cash flows other operating - - -2.92700M -0.00800M 0.15M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 11.57M -1.12000M -1.61900M
Change in working capital -4.34000M -26.88400M -0.60800M 1.11M -1.69600M
Stock based compensation 3.99M 3.18M 1.46M 0.74M 0.63M
Other non cash items 5.52M -0.31100M 0.12M 0.04M 0.17M
Free cash flow 24.63M -17.85000M -4.28100M -1.06900M -2.25900M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRPH
ProPhase Labs Inc		 0.0046 3.37% 0.14 - 10.09 2.65 2.38 3.02 -9.0334
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

ProPhase Labs Inc

711 Stewart Avenue, Garden City, NY, United States, 11530

Key Executives

Name Title Year Born
Mr. Ted William Karkus Chairman & CEO 1959
Ms. Monica Brady Chief Accounting Officer 1977
Ms. Alice Lioi Exec. VP & Co-COO NA
Mr. Jason Karkus Exec. VP & Co-COO NA
Mr. Sergio Miralles Exec. VP & Chief Information Officer of ProPhase Diagnostics NA
Mr. Billy Joe White Consultant 1961
Mr. Jed A. Latkin Chief Operating Officer & Head of Finance Department 1974
Mr. Robert A. Morse Jr. Controller, Principal Financial Officer & Principal Accounting Officer 1975
Mr. Sergio Miralles Executive VP & Chief Information Officer NA
Mr. Jason Karkus President of Nebula Genomics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.